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Summary
The intermolecular communication within NRPS com-
plexes relies on the coordinated interplay of donor and
acceptor communication-mediating (COM) domains.
In this study, the potential of COM domains was ex-
ploited in vivo by establishing a system for the true bio-
combinatorial synthesis of lipopeptides via directed
reprogramming of a natural NRP biosynthetic assem-
bly line (i.e., surfactin). By means of COM domain
swapping, these experiments verified the decisive
role of COM domains for the control of protein-protein
interactions between NRPSs, demonstrated the func-
tionality of COM domain pairs even in the context of
a heterologous host and NRPS system, and allowed
for the intended skipping of a biosynthetic enzyme
within a multienzymatic biosynthetic complex. Ulti-
mately, abrogation of the selectivity barrier provided
by COM domains afforded the successful simulta-
neous, biocombinatorial synthesis of distinct lipopep-
tide products.
Introduction
Nonribosomal peptides (NRPs) and polyketides (PKs)
represent two diverse groups of pharmacologically im-
portant natural products, which are synthesized by large
multimodular assembly lines, termed nonribosomal
peptide synthetases (NRPSs) and polyketide synthases
(PKSs), respectively [1]. Prominent examples include
antibiotics like vancomycin and erythromycin, antitumor
drugs like bleomycin and epothilone, and immunosup-
pressants like cyclosporine and FK506. According to
the molecular logic employed by NRPSs and PKSs, the
biosynthesis of a defined product relies on the selectiv-
ity of individual modules and their coordinated interplay.
In multienzyme complexes, which actually stand for
the vast majority of known assembly lines, biosynthesis
also requires the proper interaction between partner en-
zymes and concomitantly prevention of undesired inter-
actions between nonpartner enzymes.
In the latter context, correct channeling of reaction in-
termediates along an assembly line is provided, at least
for the most part, by short terminal structures, referred
to as PKS docking domains [2, 3] and NRPS communi-
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Drive, Kalamazoo, MI 49009.cation-mediating (COM) domains [4, 5]. In various stud-
ies, it has been shown that matching pairs of donor and
acceptor domains promote the correct positioning of
enzymes within multienzyme complexes and the selec-
tive translocation of intermediates between adjacent
synth(et)ases. The NMR structure of a cognate pair of
donor and acceptor docking domains revealed that in
the case of the erythromycin biosynthetic system, the
complex contains two distinct, noninteracting four-a-
helix bundles [6]. Interestingly, based on secondary
structure predictions, NRPS COM domains are likewise
believed to possess a-helical structures that may pro-
vide the interfaces for the selective differentiation
between partner and nonpartner NRPSs [5].
Despite obvious similarities like terminal localization
and function, there are many striking differences be-
tween NRPS COM domains and PKS docking domains:
first, the NMR structure suggests that C- and N-terminal
PKS docking domains comprise 80–100 and 20–30
amino acid residues, respectively [6]. In contrast, based
on domain swapping experiments, donor and acceptor
NRPS COM domains appear to be significantly shorter,
comprising only 15–30 amino acid residues, respec-
tively [4, 5]. Second, it has been shown that type I
PKSs are composed of two identical subunits [7, 8].
This organization was also reflected in the NMR struc-
ture of the PKS docking domain complex [6], suggesting
that dimerization represents an important aspect of pro-
tein-protein communication between PKSs. Interest-
ingly, sound evidence has been provided that NRPSs
are monomeric and do not form dimers [9]. This sug-
gests that the solved structure of the PKS docking do-
main complex does not apply for NRPSs and that a com-
plex of donor and acceptor COM domains must be
different from the two four-a-helix bundles, determined
for PKSs. Third, in vitro studies have demonstrated
that nonmatching pairs of docking domains between
natural partner PKSs are causing a decrease in the
rate of product formation [10, 11]. In contrast, compara-
ble experiments for NRPS systems revealed that prod-
uct formation was not just impaired, but rather com-
pletely ceased, when donor and acceptor enzymes
were equipped with noncompatible COM domains [4,
5]. All these examples clearly indicate that NRPS COM
domains and PKS docking domains represent more
than just two variations of the same theme.
As for NRPSs, in vitro studies have shown that a donor
COM domain COMDX, situated at the C terminus of an
aminoacyl- or peptidyl-donating NRPS ‘‘X,’’ and an ac-
ceptor COM domain COMAY, located at the N terminus
of the accepting partner enzyme ‘‘Y,’’ form a compatible
(cognate) pair that is crucial for establishing the produc-
tive interaction between both enzymes [4, 5]. In contrast,
within a hypothetical assembly line ‘‘X-Y-Z,’’ the COM
domains COMDX and COM
A
Z of the nonpartner NRPSs
‘‘X’’ and ‘‘Z’’ are considered incompatible (noncognate),
preventing their futile contact. Accordingly, the estab-
lishment of a defined assembly line and synthesis of
a distinct NRP product is ensured by the grouping of
exclusively cognate pairs of COM domains.
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900Figure 1. The Surfactin Biosynthetic System
The enzymatic assembly line of surfactin consists of three NRPSs, encoded by the polycistronic genes srfA-ABC (A). The synthetases SrfA-A,
SrfA-B, and SrfA-C are composed of three, three, and one module(s), respectively (B). Two cognate pairs of COM domains, COMDSrfA-A/
COMASrfA-B and COM
D
SrfA-B/COM
A
SrfA-C, facilitate the selective interaction between partner enzymes. Within this study, the first COM domain
pair was replaced by means of domain swapping on the genetic level against different cognate, miscognate, and noncognate sets of COM
domains (C).Without the selectivity provided by different pairs of
cognate COM domains, the enzymes of a given NRP
biosynthetic system could arrange randomly, which
eventually would lead to the synthesis of a vast array of
peptide products. A corresponding abrogation of this
selectivity barrier can be achieved by equipping all
donor and acceptor enzymes of a multienzyme bio-
synthetic system with the same (cognate) donor and
acceptor COM domains, respectively. A corresponding
‘‘universal communication system’’ (UCS) was recently
established in vitro, yielding the expected and intended
combinatorial biosynthesis of NRPs [5].
The presented study aimed on harnessing the bio-
combinatorial potential of COM domains for the first
time in vivo and within the context of natural multi-
enzyme NRP biosynthetic complex. To this end, differ-
ent pairs of COM domains were exploited, in order to
achieve a specific reprogramming of a biosynthetic
assembly line and to establish a system for true combi-
natorial NRP biosynthesis. As a model system, the sur-
factin biosynthetic complex of the well-studied gram-
positive bacterium Bacillus subtilis was chosen. As
shown in Figure 1, the biosynthetic assembly line con-
sists of three NRPSs (SrfA-A, SrfA-B, and SrfA-C).
Thus, taken into consideration the described model for
the control of protein-protein interactions, the surfactin
biosynthetic complex was proposed to contain two cog-
nate pairs of COM domains, COMDSrfA-A/COM
A
SrfA-B and
COMDSrfA-B/COM
A
SrfA-C, facilitating the selective inter-
action of the three synthetases and, hence, the specific
formation of the lipoheptapeptide antibiotic.
We report herein the substitution of the first COM
domain pair COMDSrfA-A/COM
A
SrfA-B, facilitating the se-
lective interaction between SrfA-A and SrfA-B, against
various cognate, miscognate, and noncognate sets of
COM domains. The consequences of the corresponding
in vivo COM domain swaps were investigated bymeans of HPLC, HPLC/MS, and high-resolution MS
analysis.
Results
General Considerations for the Generation
of In Vivo COM Domain Swaps
The reprogramming of the surfactin biosynthetic com-
plex was accomplished via a well-established two-step
genetic marker exchange method [12–14]. The approach
uses consecutive gene disruption and reconstitution,
which are both monitored by a selectable marker (Fig-
ure 2). However, for the model system under investi-
gation, exploitation of this procedure required some
special considerations.
First, the integration of a selectable marker (mls) at the
transition between srfA-A and srfA-B not only causes the
envisioned disruption of the srfAbiosynthetic operon but
also disables the coexpression of the small competence
regulator gene comS, situated in a different reading
frame within the coding region of srfA-B (see Figure 1)
[15]. The corresponding gene product (ComS) has been
shown to be essential for the establishment of the host
organism’s natural competence [16]. In order to maintain
the genetic competence required for the second trans-
formation step, a second copy of comS was integrated
into a different genetic locus (amyE) within the chromo-
some of B. subtilis ATCC 21332. The resulting B. subtilis
strain AM1 was then transformed with the knockout plas-
mid pCC63 to give the MLS resistant srfA disruption
strainB. subtilisCC64. The genetic integrity of both con-
structs, AM1 and CC64, was verified by Southern blot
and PCR analysis (data not shown).
Both strains, AM1 and CC64, were also tested for
surfactin production. To this end, butanolic extracts of
the cultured broths of the two Bacillus strains were ana-
lyzed by RP-HPLC and FT-ICR-MS, enabling even the
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For AM1, these tests revealed that the integration of a
second copy of the comS gene had—as anticipated—
no influence on lipoheptapeptide production (Fig-
ure 3A). As shown, surfactin represents a mixture of
cyclic lipopeptides, predominantly consisting of the
peptide core LGlu-LLeu-DLeu-LVal-LAsp-DLeu-LLeu,
and a b-hydroxyl fatty acid with chain lengths of 12 to16
carbon atoms (Figure 3A, chemical structure). Given their
slight differences in retention time, RP-HPLC analysis of
natural surfactin produces a signature finger pattern,
with the main peaks being derivatives with a b-hydroxyl
fatty acid, constituted of 13 (Figure 3A, structure II:
Figure 2. COM Domain Swapping
Transformation of B. subtilis AM1 with pCC63 led to homologous
recombination and disruption of the srfA operon (A). The resulting
strain CC64 was then cotransformed with the helper plasmid
pCm::Tc and the reconstitution plasmid (e.g., pCC83) to generate
the desired COM domain swap (B).n = 2) and 14 (n = 3) carbon atoms, respectively. In con-
trast, in the case of disruption mutant CC64, the analyses
unequivocally verified the expected surfactin-deficient
phenotype.
The second, potential problem concerned the recon-
stitution of the srfA operon. In fact, transformation of the
srfA disruption construct B. subtilis CC64 with a given
COM domain swapping plasmids (i.e., pCC83) not only
led to the desired reconstitution of the biosynthetic sys-
tem but also the loss of the mls resistance cassette (Fig-
ure 2). Regrettably, there is no possibility to directly
select for the loss of this genetic marker. In order to still
allow for a positive selection, congression experiments
were carried out with a given reconstitution plasmid
along with the self-replicable helper plasmid pCm::Tc,
mediating tetracyline resistance [17]. Following cotrans-
formation, cells were first selected for the presence of
the helper plasmid and only then screened for the de-
sired loss of the mls resistance cassette. The genetic
integrity of corresponding constructs was analyzed
by PCR and verified by DNA sequencing of an about
600 bp region at the transition between srfA-A and
srfA-B. After verification of the genotype (data not
shown), the strains were tested for the production of
lipopeptide products as described above.
Reconstitution of the Wild-Type srfA Operon;
COMDSrfA-A/COM
A
SrfA-B
In a first experiment, the srfA operon was reconstituted
with the coding fragment of the native COM domain pair
COMDSrfA-A/COM
A
SrfA-B, hereby restoring the wild-type
situation observed in B. subtilis strains ATCC 21332
and AM1. Despite of being a proof-of-concept, the re-
sulting construct CC84 was important to verify that the
utilized cloning strategy (see Experimental Procedures)
had no effect on the productivity of the surfactin biosyn-
thetic system. In fact, the coding fragment of a given
COM domain pair was amplified by PCR and cloned
into the integration vector pCC78, carrying the 50 and
30 homologous regions for the marker exchange recom-
bination (see Figure 2). This cloning step was performed
in a way that ensured the maintenance of the primaryFigure 3. RP-HPLC Analysis of Butanolic Extracts Derived from B. subtilis Wild-Type and Mutant Strains
(A) ATCC 21332 (COMDSrfA-A/COM
A
SrfA-B), AM1 (second copy of comS; COM
D
SrfA-A/COM
A
SrfA-B), CC64 (disruption mutant), CC84 (COM
D
SrfA-A/
COMASrfA-B), and CC99 (COM
D
TycB/COM
A
TycC).
(B) AM1 (COMDSrfA-A/COM
A
SrfA-B), CC112 (COM
D
TycA/COM
A
TycC), CC102 (COM
D
SrfA-B/COM
A
SrfA-B), CC91 (COM
D
SrfA-B/COM
A
SrfA-C), and CC110
(COMDSrfA-A/COM
A
SrfA-C). Both lipotetrapeptides (I, light gray area) and lipoheptapeptides (II, dark gray area) were identified and characterized
by coupled HPLC/ESI-MS and FT-ICR MS analysis (Figure 4).
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902Table 1. Comparison of Determined and Estimated Production Levels
Bacillus
subtilis Strain COM Domain Pair
Lipoheptapeptide Lipotetrapeptide
Comments/Description
Area of
Absorbance
at 214 nm (in AU)a
Production
Level
(in % of wt)b
Area of
Absorbance
at 214 nm (in AU)a
Estimated
Production
Level (in % of wt)b
ATCC 21332 COMDSrfA-A/COM
A
SrfA-B 1460 6 80 100 (wt) n.d. n.d. wild-type
AM1 COMDSrfA-A/COM
A
SrfA-B 1600 6 100 110 n.d. n.d. second copy of comS
CC64 none n.d. n.d. n.d. n.d. srfA disruption
CC84 COMDSrfA-A/COM
A
SrfA-B 1110 6 100 76 n.d. n.d. srfA reconstitution
CC99 COMDTycB/COM
A
TycC 1010 6 80 69 n.d. n.d. heterologous COM
CC112 COMDTycA/COM
A
TycC n.d. n.d. 1070 6 50 (73)
c skipping
CC102 COMDSrfA-B/COM
A
SrfA-B 260 6 20 18 550 6 40 (38)
c skipping vs. UCS
CC91 COMDSrfA-B/COM
A
SrfA-C 40 6 10 3 70 6 10 (5)
c UCS
CC110 COMDSrfA-A/COM
A
SrfA-C 380 6 30 26 n.d. n.d. non- versus miscognate
n.d., not detected.
a The areas of absorbance at 214 nm were determined for at least three individual experiments by using the implemented ChemStation software
provided with the HPLC instrument. To compare the productivity per cell and take into account possible differences in growing behavior, the
determined values were normalized for the OD600nm of the cultures, used for the butanolic extraction. AU, arbitrary units.
b Production levels of mutant strains were determined by comparing the areas of absorbance at 214 nm of wild-type and mutant. The production
level calculated for the wild-type was set to 100%.
c The comparison assumes identical molar extinction coefficients at 214 nm for both lipotetra- and lipoheptapeptide. Since this is certainly not
the case, the given values for the lipotetrapeptide represent only estimations. The analytic procedure was enforced by the lack of an authentic
standard and is likely to underestimate the amount of lipotetrapeptide produced.sequences of the conserved core motifs ‘‘TPSD’’ and
‘‘QEGMLYH,’’ which were used as fusion points. This,
in turn, required the introduction of three silent point
mutations. As shown in Figure 3A and Table 1, the anal-
ysis of B. subtilis CC84 revealed that the reconstitution
construct was able to produce nearly wild-type levels
of the lipoheptapeptide surfactin, indicating that the
genetic manipulations neither resulted in a drop of prod-
uct titer nor a change in product distribution.
Activity of Heterologous COM Domains;
COMDTycB/COM
A
TycC
In order to address the question whether a heterologous
COM domain pair could replace the native COM domain
pair COMDSrfA-A/COM
A
SrfA-B, the functionality and per-
formance of COMDTycB/COM
A
TycC, derived from the
tyrocidine biosynthetic complex of B. brevis ATCC
8185, was tested. In vitro studies showed that COMDTycB
and COMATycC are forming a cognate COM domain pair,
facilitating the productive interaction between the natu-
ral partner NRPSs TycB and TycC [4]. Furthermore, the
COM domain pair could be fused to different donor
and acceptor enzymes, still facilitating their productive
interaction. On the other hand, the donor COM domain
COMDTycB is not compatible with the heterologous ac-
ceptor COM domain COMASrfA-C of SrfA-C. Taking all
this into consideration, the introduction of the coding
fragment of COMDTycB/COM
A
TycC into the chromosome
of the srfA disruption strain B. subtilis CC64 was ex-
pected to yield a restoration of surfactin production.
After verification of the correct genotype (data not
shown), the resulting strain B. subtilis CC99 was ana-
lyzed for surfactin production. As verified by HPLC, inte-
gration of the heterologous COM domain pair COMDTycB/
COMATycC only caused a minor decrease in productivity
(Figure 3A and Table 1). The product titer of 69% (com-
pared to the wild-type) indicated that the cognate COM
domains do very well maintaining their activity and mu-
tual affinity, even in the context of a heterologous host
and NRPS system.Skipping of Enzymes within an NRPS Complex;
COMDSrfA-B/COM
A
SrfA-B versus COM
D
TycA/COM
A
TycC
COM domains can be exploited to enforce the inter-
action between natural nonpartner enzymes and to pre-
vent the contact between natural partner enzymes [4, 5].
With regard to the targeted engineering of NRP biosyn-
thetic assembly line, this concept was challenged by
attempting the controlled in vivo skipping of the second
NRPS, SrfA-B, and—at the same time—establishing
a productive interaction between the trimodular initia-
tion enzyme SrfA-A and the monomodular termination
enzyme SrfA-C (see Figure 1). This was expected to
cause the rational formation of a shortened lipotetra-
peptide product. Two different strategies were pursued
in order to achieve the intended skipping of SrfA-B.
Based on in vitro studies, COMDTycA and COM
A
TycC
have been shown to form a noncognate COM domain
pair [4, 5]. Thus, no productive interaction between donor
and acceptor enzymes, carrying these two COM do-
mains, is observed.COMDTycA, however, has beenshown
to establish a miscognate interaction with COMASrfA-C,
allowing for a crosstalk between enzymes carrying these
two COM domains, even if they are derived from two dif-
ferent biosynthetic systems [4]. In vivo, when replacing
the native COM domain pair COMDSrfA-A/COM
A
SrfA-B,
the noncognate pair COMDTycA/COM
A
TycC should
consequently facilitate a controlled skipping of the tri-
modular elongation enzyme SrfA-B and a selective inter-
action between SrfA-A and SrfA-C. The latter should be
detectable by the formation of the shortened lipo-
tetrapeptide product FA-LGlu-LLeu-DLeu-LLeu-OH.
Provided that the established working model would
also apply to surfactin biosynthetic system, the COM
domain pairs COMDSrfA-A/COM
A
SrfA-B and COM
D
SrfA-B/
COMASrfA-C should represent cognate pairs of COM do-
mains, facilitating the selective interaction between
SrfA-A and SrfA-B, as well as SrfA-B and SrfA-C, re-
spectively. On the other hand, the COM domain pairs
COMDSrfA-A/COM
A
SrfA-C and COM
D
SrfA-B/COM
A
SrfA-B
had to be considered as noncognate. Hence, the latter
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903pair COMDSrfA-B/COM
A
SrfA-B was likewise expected to
facilitate a controlled skipping of the elongation module
SrfA-B, and a direct interaction between SrfA-A and
SrfA-C, when substituting the native COMDSrfA-A/
COMASrfA-B at the transition between SrfA-A and SrfA-B.
The corresponding COM domain swaps were gener-
ated, and the integrity of the resulting B. subtilis strains
CC112 (COMDTycA/COM
A
TycC) and CC102 (COM
D
SrfA-B/
COMASrfA-B) verified as described above (data not
shown). Subsequently, the lipopeptide production was
analyzed. For B. subtilis CC112, these tests revealed
the expected formation of the lipotetrapeptide FA-
LGlu-LLeu-DLeu-LLeu-OH (Figure 3B and Figure 4). As
in the case of the lipoheptapeptide, HPLC analysis re-
vealed a typical finger pattern, representative for lipo-
peptides with slight variations in the length of the b-
hydroxyl fatty acid (see Figure 3B, chemical structure of
lipotetrapeptide). The identity of lipotetrapeptide was
verified by high-resolution FT-ICR analysis (Figure 4).
The accurate quantification of the novel product was
barred, due to the lack of an authentic standard. In order
to overcome this limitation and still permit at least an
estimation of production levels, the areas of absorbance
of the corresponding UV signals at 214 nm were used
for the comparison of lipohepta- and lipotetrapeptide
production (Table 1). It should be noted that all produc-
tion levels provided refer to the comparison of areas of
absorbance at 214 nm, rather than real quantities of
the corresponding lipopeptide products. It should be
stressed that this procedure only permits an estimation
of production levels, which might underestimate the
actual amount of the lipotetrapeptide, given its fewer
number of absorbing peptide bonds.
According to this analysis, the production level of
lipotetrapeptide in B. subtilis CC112 (COMDTycA/
COMATycC) was estimated to be in the same order of
magnitude (73%) (Table 1) as observed for the full-
length lipoheptapeptide within the wild-type producer
strain. The same examination for B. subtilis CC102
(COMDSrfA-B/COM
A
SrfA-B) likewise revealed the forma-
tion of the expected lipotetrapeptide product at essen-
tially the same production level (38%) (Figure 3B and
Table 1). Surprisingly, however, the latter analysis also
revealed the simultaneous formation of the full-length
lipoheptapeptide surfactin, although at a reduced prod-
uct titer (18%). This indicates that the communication
between SrfA-A and SrfA-B was not completely abro-
gated, and that COMDSrfA-B and COM
A
SrfA-B are forming
a miscognate, rather than the expected noncognate
COM domain pair. In the context of the hybrid NRPS
system under investigation (see Figure 1), this miscog-
nate COM domain pair allows for the productive interac-
tion between SrfA-A and SrfA-B, as well as SrfA-A and
SrfA-C, and eventually formation of both lipopeptide
products.
Combinatorial In Vivo Biosynthesis;
COMDSrfA-B/COM
A
SrfA-C
The present data demonstrate the inherent potential
of COM domains for the directed reprogramming of
the NRP assembly lines. The ultimate goal of such
manipulations, however, would be a biocombinatorial
synthesis of NRPs, which should be achievable by sus-
pending the selectivity barrier, provided by COMdomains. Such abrogation, as has been recently de-
scribed in vitro on the basis of a so-called universal
communication system (UCS) [5]. In the context of the
surfactin biosynthetic complex, a similar UCS can be es-
tablished, e.g., by integration of the cognate COM do-
main pair COMDSrfA-B/COM
A
SrfA-C at the transition be-
tween the SrfA-A and SrfA-B. As a result, all donor and
acceptor enzymes of the surfactin assembly line would
be equipped with the same (cognate) pair of COM do-
mains (see Figure 1) and hence should be intercommu-
nicable. In other words, SrfA-A should equally be able
to interact with its natural partner SrfA-B (now equipped
with the compatible acceptor COM domain COMASrfA-C)
and the natural nonpartner enzyme SrfA-C. Both possi-
bilities should lead to the simultaneous formation of the
full-length lipoheptapeptide surfactin (organization of
the biosynthetic complex: SrfA-A/SrfA-B/SrfA-C) and
the shortened lipotetrapeptide FA-LGlu-LLeu-DLeu-
LLeu-OH (SrfA-A/SrfA-C). Technically also feasible
would be an interaction between two molecules of
SrfA-B, which should lead to the formation of an elon-
gated lipodecapeptide product (SrfA-A/SrfA-B/SrfA-B/
SrfA-C).
The corresponding COM domain swap was created
on the genetic level, and the integrity of the resulting
B. subtilis strain CC91 verified (data not shown). HPLC
analysis of the biosynthetic products synthesized by
the reprogrammed assembly line clearly revealed the
expected formation of lipotetra- and lipoheptapeptide,
while no lipodecapeptide could be observed (Figure 3B).
Intriguingly, however, the production level of B. subtilis
CC91 (COMDSrfA-B/COM
D
SrfA-C) was relatively low, yield-
ing about 1/20th of the amount of surfactin produced by
the wild-type under the same conditions (Table 1). Also
interesting was the observation that the specificity of
the reprogrammed NRPS complex was shifted in favor
of the shortened lipotetrapeptide (ratio lipotetrapep-
tide-to-lipoheptapeptide: approximately 2:1), although
Figure 4. FT-ICR MS Analysis
High-resolution FT-ICR MS unequivocally revealed the identity of
the lipotetrapeptides FA-LGlu-LLeu-DLeu-LLeu-OH. For the sake
of clarity, only the [M+K+] peaks were annotated.
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ner enzymes SrfA-A and SrfA-C.
Discussion
Ever since elucidation of the modular organization of
NRP and PK biosynthetic complexes, the reprogram-
ming of their enzymatic assembly lines and eventually bi-
ocombinatorial synthesis of novel natural product deriv-
atives represented the ultimate goals of research in this
area [18, 19]. For NRPs, corresponding efforts included
(1) the exchange of A-PCP minimal modules [13, 14],
(2) the exchange or deletion of C-A-PCP elongation
modules [20, 21], (3) the change-of-selectivity mutagen-
esis of A domains [12], and (4) the translocation of the
terminal, product-releasing Te domains [22]. Although
all these approaches led to the formation of the antici-
pated NRP products, the genetic manipulations were
usually involved with significant drops in product titer
due to ambiguous problems in the interplay between na-
tive and newly introduced catalytic domains and/or the
processing of alternative substrate amino acids.
The presented study aimed on harnessing the poten-
tial of COM domains for the directed reprogramming
of the surfactin biosynthetic complex and on establish-
ing of an in vivo system for true biocombinatorial synthe-
sis of lipopeptides. To this end, the first COM domain
pair of the surfactin biosynthetic complex (COMDSrfA-A/
COMASrfA-B), facilitating the selective interaction be-
tween SrfA-A and SrfA-B, was substituted against
various cognate, miscognate, and noncognate sets of
COM domains.
In a first set of experiments, the disrupted surfactin
biosynthetic gene cluster of B. subtilis CC64 (see Fig-
ure 2) (genotype: srfA-A::mls::srfA-B) was reconstituted
with the gene fragments encoding for the native COM
domain pair COMDSrfA-A/COM
A
SrfA-B and the heterolo-
gous COMDTycB/COM
A
TycC, derived from the tyrocidine
biosynthetic system, respectively. Both COM domain
pairs, featuring compatible (cognate) COM domains, fa-
cilitated the productive interaction between SrfA-A and
SrfA-B and consequently led to the expected restoration
of surfactin biosynthesis. Just as important, the gener-
ated (hybrid) NRPS systems revealed essentially the
same productivity as the wild-type. This represents
a major improvement toward previous experiments,
where already the simple reconstitution of the wild-
type system was connected with significant reductions
in product titer [13, 14, 20].
Similarly to the first experiments, the heterologous,
noncognate pair COMDTycA/COM
A
TycC was exploited to
(1) bypass the trimodular SrfA-B, (2) facilitate—due to
the crosstalk between COMDTycA and COM
A
SrfA-C—a di-
rect interaction between the natural nonpartner NRPSs
SrfA-A and SrfA-C, and (3) cause the directed synthesis
of the novel lipotetrapeptide product FA-LGlu-LLeu-
DLeu-LLeu-OH. Utilization of the cognate COM domain
pair COMDSrfA-B/COM
A
SrfA-C, on the other hand, led to
the establishment of a so-called universal communica-
tion system (UCS) [5], in which all donor and acceptor
NRPSs were equipped with the same (compatible)
COMD and COMA domains, respectively. Due to the ab-
rogated selectivity of protein-protein communication,
the resulting universal communication system (UCS)was capable of biocombinatorial peptide synthesis. In
fact, the NRPS system was able to form different assem-
bly lines (SrfA-A/SrfA-B/SrfA-C and SrfA-A/SrfA-C) for
the synthesis of the lipoheptapeptide and the lipotetra-
peptide, at the same time and in roughly comparable
amounts.
Given the compatibility of all donor and acceptor COM
domains, (theoretically) also feasible should be the com-
munication between two molecules of SrfA-B. This
would lead to the formation of a third assembly line
(SrfA-A/SrfA-B/SrfA-B/SrfA-C), eventually resulting in
the synthesis of an elongated lipodecapeptide. How-
ever, analysis of the butanolic extracts, obtained from
the supernatant and the pellet fraction of B. subtilis
crude extracts revealed no evidence for such product.
The absence of lipodecapeptide formation could be
due to (1) the toxicity of the product, (2) the incapability
of the SrfA-C Te domain to process the alternative lipo-
decapeptidyl-PCP substrate, (3) the hydrolysis of the
unnatural reaction intermediates from the protein tem-
plate as catalyzed by the cleaning enzyme Srf-Te [23],
or (4) the inherent instability of the decapeptide product.
The most likely explanation, however, is the limited avail-
ability of SrfA-B. In fact, the polycistronic organization
of the surfactin biosynthetic genes ensures for the pro-
duction of equimolar quantities of SrfA-A, SrfA-B, and
SrfA-C, whereas the formation of the biosynthetic as-
sembly line of the lipodecapeptide would require an
excess of SrfA-B.
The most intriguing result of this study, though, was
the determination of both lipopeptide products (rather
than just the lipotetrapeptide) when using the presumed
noncognate COM domain pair COMDSrfA-B/COM
A
SrfA-B.
From previous studies on the tyrocidine biosynthetic
complex, it was known that COMD and COMA domains
of nonpartner enzymes are incompatible, supposedly
to prevent the futile contact between, i.e., the first
(TycA) and third (TycC) enzyme of the NRPS assembly
line [4, 5]. Against this background, it was expected
that the putative incompatible COM domain pair
COMDSrfA-B/COM
A
SrfA-B would provide a skipping of
SrfA-B and a direct interaction between the natural non-
partner enzymes SrfA-A and SrfA-C, when introduced at
the transition between SrfA-A and SrfA-B. The observed
biocombinatorial synthesis of both lipopeptides, how-
ever, pointed toward a still functional interaction be-
tween the latter two enzymes.
How can this be explained? Previous in vitro studies
indicated that the homology between COM domains
might provide a clue for the possible crosstalk between
natural nonpartner NRPSs. In this context, an interac-
tion between donor enzymes carrying COMDTycA and
acceptor enzymes bearing the (mis)cognate domains
COMATycB, COM
A
GrsB, or COM
A
SrfA-C was experimentally
proven [4, 5]. No interaction, in contrast, was observed
between enzymes, carrying COMDTycA and the noncog-
nate COMATycC. The average sequence homology among
the mentioned (miscognate) acceptor COMA domains of
TycB, GrsB, and SrfA-C amounts to 79%, compared to
only 50% identity observed between the (noncognate)
acceptor COMA domains of TycB and TycC. Interestingly,
the sequence identity between the two COMA domains
of the surfactin biosynthetic complex, COMASrfA-B and
COMASrfA-C, amounts to astonishing 63%, which may still
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pair, COMDSrfA-A/COM
A
SrfA-B and COM
D
SrfA-B/COM
A
SrfA-C,
mutually interchangeable.
Recently, we also proposed a five-residue model to
describe the interaction between donor and acceptor
COM domains and to predict the respective amino
acid residues, facilitating their contact [5]. According
to this model, a cognate pair of COM domains forms
a leucine-zipper like motif, with COMD and COMA each
contributing one helix. The proposed selectivity-confer-
ring residues—five from each COM domain—are deter-
mined based on their relative location toward the highly
conserved core motifs ‘‘TPSD’’ (COMD) and ‘‘L(T/S)P(M/
L)QEG’’ (COMA) (Figure 5A). Having done this assign-
ment for all twelve COM domain pairs of the tyrocidine,
gramicidin S, surfactin, lichenisin, fengycin, and bacitra-
cin biosynthetic complexes, it was found that more than
96% of the 120 putative selectivity-conferring residues
are either polar or charged. Furthermore, astounding
59 of 60 proposed amino acids pairs (>98%) lead to
the establishment of productive (nonrepulsive) polar or
electrostatic interactions [5].
It should be stressed that this five-residue model was
postulated based on the in silico analysis of NRPSs. It is,
though, supported by the observation that major differ-
ences between (mis)cognate and noncognate (accep-
tor) COM domains occur every three amino acid resi-
dues, this way, matching the known rise per repeating
unit within an a-helical structure. Even more compelling,
the model is in agreement with biochemical data
obtained for a mutational analysis of the acceptor COM
domain COMATycC (Figure 5B) [5].
As for the surfactin biosynthetic complex, the five-
residue model predicts that the productive interaction
between two partner enzymes requires at least four
proliferous (polar or electrostatic) contacts (Figure 5).
The cognate COM domain pair COMDSrfA-B/COM
A
SrfA-C
also shows one, presumably repulsive contact (note:
this is the only mismatch observed so far in this model)
between a Glu residue and an Asp residue. In contrast,
the proven noncognate pair COMDTycA/COM
D
TycC does
establish one repulsive but only three proliferous con-
tacts. Just as important, when comparing the quality
of contacts, it is found that the same number of electro-
static and polar interactions is formed between
COMDSrfA-B and the cognate COM
A
SrfA-C or the mis-
cognate COMASrfA-B. This would explain the observed
productive interaction between SrfA-A and SrfA-B
in the hybrid NRPS systems of CC102 (COMASrfA-B/
COMDSrfA-B) and the resulting biocombinatorial syn-
thesis of lipohepta- and lipotetrapeptide. Interestingly,
the model also predicts a miscognate interaction be-
tween the COMDSrfA-A and COM
A
SrfA-C (Figure 5), which
was experimentally confirmed by constructing the cor-
responding COM domain swap (data not shown).
In the resulting hybrid NRPS system of strain CC110 (ge-
notype: srfA-A::COMDSrfA-A-COM
A
SrfA-C::srfA-B), SrfA-A
was able to establish a miscognate interaction with
SrfA-B, leading to a robust restoration of surfactin pro-
duction (26%) (Figure 3B and Table 1).
The predicted differences between selectivity-confer-
ring residues of (mis)cognate and noncognate COM do-
main pairs appear to be rather minor. It was, however,
already shown that as little as one point mutation canbe sufficient to prevent a COM domain from interacting
with its native partner and/or to render it, instead, a com-
patible counterpart of a natural nonpartner enzyme [5].
Hence, the described five-residue model provides a
plausible explanation for the product patterns observed
in the course of our COM domain swap experiments. On
the other hand, it leaves open the question of how the
formation of a defined biosynthetic complex (and even-
tually synthesis of a specific peptide product) is con-
trolled, when both partner and nonpartner enzymes
are equipped with compatible (cognate or miscognate)
pairs of COM domains. In this context, it is interesting
to realize that the COM domain pair COMDSrfA-A/
COMASrfA-C only causes a miscognate interaction be-
tween natural partner enzymes (i.e., SrfA-A and SrfA-B
in B. subtilis CC110), but not nonpartner NRPSs (i.e.,
SrfA-A and SrfA-C in B. subtilis CC110 or ATCC 21332).
This may be an indication for additional subsidiary struc-
tures, situated outside the COM domains, which may
influence protein-protein communication.
Where could such additional subsidiary structures be
located? One of the best-studied systems to narrow
down this question is the dimodular TycA/TycB1 (do-
main organization: PheA-PCP-E-COMD/COMA-C-ProA-
PCP). Deletion studies showed that the E domain of
TycA has little or no impact on the protein-protein inter-
action between both enzymes [5]. Mispriming experi-
ments and mutational studies revealed that the C do-
main of TycB1 selects for the stereochemistry of the
donor substrate [24, 25]. Additional influence of the do-
nor substrate on protein-protein interaction, however,
Figure 5. Five Residue Model
(A) The highly conserved core motifs ‘‘TPSD’’ (COMD) and
‘‘L(T/S)P(M/L)QEG’’ (COMA) act as structural anchors for the deter-
mination of putative selectivity-conferring residues, e.g., within the
COM domain pair COMDSrfA-B/COM
A
SrfA-C.
(B) Proposed interactions within representative cognate, miscog-
nate, and noncognate COM domain pairs. Electrostatic interactions
are indicated by squares, polar interactions by vertical bars, and
putative repulsive interactions by minuses.
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906has not been observed [4, 5]. That leaves A and PCP do-
mains as the most likely candidates, whereby PCP do-
mains have been frequently shown to possess recogni-
tion elements (particularly helix 3 of the four-a-helix
bundle), which have a major impact on interaction be-
tween acyl-S-Ppant PCPs and associated domains
[26, 27]. Further studies are required to clarify this point.
Despite such additional structures that may have an
influence on protein-protein communication, our study
clearly confirmed the decisive role of COM domain pairs
for the establishment and/or prevention of productive in-
teractions within NRP biosynthetic complexes. These
properties could be exploited for (1) the restoration of
surfactin biosynthesis with a heterologous COM domain
pair, (2) the directed skipping of SrfA-B within the surfac-
tin biosynthetic assembly line, (3) the substantiation of
the soundness of the five-residue model for the descrip-
tion of the interactions between donor and acceptor
COM domains, and (4) the establishment of a hybrid sys-
tem for true biocombinatorial synthesis of lipopeptides.
Significance
NRPSs catalyze the formation of structurally diverse
and pharmacologically important peptide natural
products. Given their modular organization, they hold
an enormous potential for the generation of novel bio-
active compounds. Up until now, corresponding ap-
proaches were generally limited to module swaps,
which (1) require major manipulations of the biosyn-
thetic template, (2) were mostly connected with signif-
icant drops in product titer, and (3) constitutionally
lead to the synthesis of only one product per experi-
ment. A powerful alternative is provided by the exploi-
tation of COM domains, which have an important role
during the intermolecular channeling of reaction inter-
mediates along the biosynthetic assembly line. In the
presented study, the inherent potential of COM do-
mains was utilized for the first time in vivo for the
directed reprogramming of a NRP assembly line (i.e.,
surfactin) and the setting up of a system for true bio-
combinatorial peptide synthesis. These experiments
demonstrated the functionality of COM domains even
in the context of a heterologous host and NRPS sys-
tem and allowed for the intended skipping of a biosyn-
thetic enzyme within the multienzyme NRPS complex.
Abrogation of the selectivity barrier provided by COM
domains afforded the simultaneous, biocombinatorial
synthesis of distinct lipopeptide products. Impor-
tantly, most of these manipulations were connected
with only minor reductions in the production level
(average: 51% of wild-type). Future applications of
COM domains will include (1) the generation of bio-
combinatorial libraries of pharmacologically impor-
tant NRPs, (2) the coordinated crosstalk between
differentNRPbiosynthetic system, and (3) thesegmen-
tation of large monoenzymatic NRP assembly line into
easier manageable, multienzymatic complexes. An
improved understanding of the structural basis of the
interaction betweendonor and acceptor COMdomains
may also allow the development of inhibitors for the
prevention of protein-protein communication, e.g., in
cases were the NRP product is involved in the viru-
lence of a given pathogenic producer strain.Experimental Procedures
Bacterial Strains and Culture Media
Strains of Bacillus subtilis (see the Supplemental Data available with
this article online) were grown in Difco sporulation medium (DSM)
[28] or modified SpII medium [13]. The media were supple-
mented—when applicable—with 1 mg/ml erythromycin, 25 mg/ml lin-
comycin, 5 mg/ml chloramphenicol, and/or 10 mg/ml tetracycline.
Escherichia coli strains were grown in Luria Broth (LB) medium,
supplemented with 50 mg/ml amplicillin.
Plasmid Construction
When not indicated otherwise, DNA fragments were amplified from
chromosomal DNA of B. subtilis ATCC 21332 with either KOD Hot
start DNA Polymerase (Novagen, Merck Biosciences, Bad Soden,
Germany) or the ‘‘Expand long template PCR system’’ (Roche, Man-
nheim, Germany) in accordance to the manufacturer’s protocols.
The primers (Supplemental Data) were purchased from MWG-Bio-
tech (Ebersberg, Germany) and utilized to introduce the desired
terminal restriction sites for the subsequent cloning of PCR prod-
ucts. Standard procedures were applied for DNA manipulations
[29], and DNA sequencing confirmed the identity of all plasmids
constructed.
The 1.6 kb fragment 0srfA-A3 and the 1.4 kb fragment srfA-B50
were amplified with the oligonucleotides EPI_F and srf_14R as well
as srf_11F and EPI_R, respectively. Based on the 21 bp overlapping
region in EPI_F and EPI_R, both fragments were used simulta-
neously as template for the subsequent fusion PCR with the oligonu-
cleotides srf_11F and srf_14R. The resulting PCR product was mod-
ified withNcoI and XbaI and cloned into the E. coli expression vector
pQE60 previously cut in the same manner, to give pCC42. Inverse
PCR, using the oligonucleotides srf_22F and srf_23R, was used
for engineering a BamHI restriction into pCC42 to give pCC50. Sub-
sequently, this restriction site was exploited for cloning of a 1.6 kb
BamHI/BglII fragment, containing the mls resistance cassette, from
pDG646 into pCC50 to give the final disruption vector pCC63 [30].
The 3 kb fragment 0srfA-A3-srfA-B50 was amplified by using the
oligonucleotides srf_11F and srf_14R. After digestion with NcoI
and XbaI, the fragment was ligated into pQE60 to give pCC77. Sub-
sequently, inverse PCR with the oligonucleotides 50-pQE/srfAB_inv
and 30-pQE/srfAB_inv was used for engineering of the restriction
sites AvrII and Acc65I. The resulting plasmid pCC78 was then
used for cloning of all COM domain pairs investigated in this study.
To this end, the corresponding gene fragments were amplified via
PCR, terminally modified with NheI and BsrGI, and ligated into
pCC78 previously cut with AvrII and Acc65I. The 150 bp gene frag-
ment of COMDSrfA-A/COM
A
SrfA-B was amplified using primers
50-srfAB_COM and 30-srfAB_COM to yield (after cloning) pCC83.
Similarly, the gene fragment of COMDSrfA-B/COM
A
SrfA-C was obtained
by using the oligonucleotides 50-srfBC_COM and 30-srfBC_COM, to
construct pCC85. The 246 bp fragment of COMDTycB/COM
A
TycC was
amplified from chromosomal DNA of B. brevis ATCC 8185 by using
the oligonucleotides 50-TycBC_COM and 30-TycBC_COM, to obtain
pCC92. The 259 bp fragment COMDTycA/COM
A
TycC was amplified
from pQE61-TycA-(C1)TycB1 by using the oligonucleotides 50-
tycAB_COM und 30-tycAB_COM, to give pCC106. Fusion-PCRs
were carried out for the construction and amplification of the gene
fragments of the miscognate COM domain pairs COMDSrfA-B/
COMASrfA-B and COM
D
SrfA-A/COM
A
SrfA-C. To this end, the 459 bp
fragment of COMASrfA-B was amplified by using the oligonucleotides
50-srfB1_SOE(srfB3) and 30-srfB1_SOE(srfB3), while the 470 bp frag-
ment of COMDSrfA-B was amplified by using the oligonuleotides
50-srfB3_SOE(srfB1) and 30-srfB3_SOE(srfB1). After purification,
both DNA fragments were combined and used as template for the
amplification of the 165 bp fragment of COMDSrfA-B/COM
A
SrfA-B by
using the oligonucleotides 50-srfBC_COM and 30-srfAB_COM. Clon-
ing into pCC78 yielded pCC98. Analogously, the 461 bp fragment
of COMDSrfA-A was amplified by using 5
0-srfA3_SOE(srfC) and
30-srfA3_SOE(srfC), whereas the 493 bp fragment of COMASrfA-C
was amplified by using 50-srfC_SOE(srfA3) and 30-srfC_SOE(srfA3).
After purification, both fragments were used as template for the
amplification of the 183 bp fragment of COMDSrfA-A/COM
A
SrfA-C by
using the oligonucleotides 50-srfAB_COM and 30-srfBC_COM.
Cloning into pCC78 gave pCC97.
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Transformations were carried out as described by Klein et al. [31].
The genotypes were verified via PCR and/or Southern blotting anal-
ysis. Transformation of B. subtilis ATCC 21332 with ApaI/SacII-line-
arized pKE27 [32] resulted in the CmR mutant AM1, which contains
a second copy of comS in the amyE site. B. subtilis AM1 was trans-
formed with pCC63, previously linearized with XbaI and XhoI, to give
the CmR and MLSR disruption strain CC64 (genotype: 0srfA-A-mls-
srfA-B0).
Generation of the desired COM domain swaps was achieved by
congression experiments. To this end, the disruption strain CC64
was transformed with 1 mg of the corresponding linearized reconsti-
tution plasmid (pCC83, pCC92, pCC106, pCC98, pCC85, or pCC97,
respectively), along with 50 ng of the helper plasmid pCm::Tc,
carrying a selectable tetracycline resistance marker [17]. Transform-
ants were selected on CmR and TcR, followed by a screening on
MLSS. These transformation gave the B. subtilis mutants CC84
(srfA-A::COMDSrfA-A-COM
A
SrfA-B::srfA-B), CC99 (srfA-A::COM
D
TycB-
COMATycC::srfA-B), CC112 (srfA-A::COM
D
TycA-COM
A
TycC::srfA-B),
CC102 (srfA-A::COMDSrfA-B-COM
A
SrfA-B::srfA-B), CC91 (srfA-A::
COMDSrfA-B-COM
A
SrfA-C::srfA-B), and CC110 (srfA-A::COM
D
SrfA-A-
COMASrfA-C::srfA-B), respectively.
Product Analysis
Purification of lipopeptides was performed as described previously
[13]. Extracts were analyzed by RP-HPLC on a 1100 series instru-
ment (Agilent, Waldbronn, Germany) with a CC250/3 Nucleosil
120-3C8 column (Macherey & Nagel, Du¨ren, Germany), equilibrated
to 70% buffer B (buffer A, 0.05% [v/v] formic acid in H2O; buffer B,
0.045% [v/v] formic acid in methanol). Samples were separated by
applying a linear gradient to 95% buffer B over 30 min at a flow
rate of 0.3 ml min21. Products were determined at 214 nm and quan-
tification of the lipotetra- and lipoheptapeptides was achieved by
integration of the corresponding UV signals.
Online mass spectrometric analysis was performed with a Finni-
gan LTQ-FT mass spectrometer (Thermo Electron, Bremen, Ger-
many). Samples were measured in the positive ion mode (mass
range: 198–1,980) with a Fourier transformation (FT) resolution of
100,000. Parameters were as follows: ion spray voltage 4.5 kV,
sheath gas 50 units, auxiliary gas ten units, capillary temperature
330C with a capillary voltage of 41 V and a tube lens setting of
100 V.
Supplemental Data
Supplemental Data include the strains, plasmids, and oligonucleo-
tides used in this study and are available at http://www.chembiol.
com/cgi/content/full/13/8/899/DC1/.
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